仙琚制药(002332) - 仙琚制药投资者关系管理信息

Financial Performance - In the first three quarters of 2024, the company achieved operating revenue of 32.37 billion CNY, maintaining the same level as the previous year [2] - Net profit attributable to shareholders was 12.42% with a non-recurring net profit of 5.21 billion CNY, representing a year-on-year growth of 12.82% [2] - In Q3 2024, the company reported operating revenue of 10.99 billion CNY, a year-on-year increase of 12.17% [2] - Gross margin for the first three quarters was 55%, up from 51.3% in the same period last year, indicating an increase of approximately 3.7% [2] Expense Management - Selling expenses for the first three quarters were stable at 22% compared to the previous year [2] - Research and development expenses amounted to 450 million CNY, with a research expense ratio of 7%, an increase of approximately 1.4 percentage points year-on-year [2] Product Performance - The company’s formulation revenue for Q3 was approximately 19.3 billion CNY, reflecting an 8% year-on-year growth, driven by increases in anesthetic muscle relaxants and respiratory products [2] - Sales of gynecological and women's health products reached approximately 3.4 billion CNY, maintaining the same level as the previous year [3] - Anesthetic muscle relaxants generated about 1 billion CNY in sales, a year-on-year increase of approximately 20% [3] - Respiratory products achieved sales of approximately 6.15 billion CNY, with a year-on-year growth of about 32% [3] - Sales of dermatological products reached approximately 1.88 billion CNY, reflecting a year-on-year increase of about 20% [3] New Product Development - The company is actively developing new products, including the long-acting progesterone injection and inhalation formulations, with expected submissions for approval in 2025 [5][6] - The company has launched several new products, including the new formulation of progesterone, which is expected to complete clinical trials by Q4 2024 [5][6] Market Strategy - The company is focusing on international expansion and innovation as key development directions, aiming to enhance product registration capabilities and quality [6] - Collaboration with Newchem has been established for 11 products, enhancing competitiveness in the international market [6]